Gene therapy for rare heart disease passes early safety check

NCT ID NCT07050160

ENROLLING_BY_INVITATION Disease control Sponsor: Lexeo Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor them for years to see if the treatment remains safe and continues to help control the disease. The goal is to understand long-term effects, not to test if it works as a cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LX2020 gene therapy
What this could lead to: If successful, this could show that a single dose of gene therapy safely controls arrhythmogenic cardiomyopathy long-term, reducing the need for other treatments.
What could go wrong: This is a very small, early-stage follow-up study with only 10 participants. It is not designed to prove the therapy works, and long-term risks or loss of effect are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arrhythmogenic right ventricular cardiomyopathy arrhythmogenic right ventricular dysplasia 9 cardiac arrest cardiomyopathy Death, Sudden, Cardiac

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARRHYTHMOGENIC CARDIOMYOPATHY PKP2-ACM PKP2-ARVC

Contacts and locations

Locations

University of Michigan

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.